PerkinElmer Inc (PKI)
133.26
+2.26
(+1.73%)
USD |
NYSE |
Mar 31, 16:00
133.29
+0.03
(+0.02%)
Pre-Market: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 16.85B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -23.46% |
| Valuation | |
| PE Ratio | 29.10 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.275 |
| Price to Book Value | 2.282 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.07 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5952 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 41.73% |
News
Headline
Wire
Time (ET)
Yahoo
03/13 16:05
Yahoo
03/11 08:30
Yahoo
03/09 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/03/2023* | -- | Results | Q1 2023 | -- | 1.02 | -- | |
| 05/03/2023* | 17:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 02/14/2023 | -- | Results | Q4 2022 | 1.70 | 1.66 | 2.34% | |
| 02/14/2023 | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/08/2022 | -- | Results | Q3 2022 | 1.51 | 1.48 | 2.37% | |
| 11/08/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | 2.32 | 2.01 | 15.49% | |
| 08/04/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
| PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes immunodiagnostics, reproductive health, and applied genomics, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software. |
| URL | https://www.perkinelmer.com |
| Investor Relations URL | https://ir.perkinelmer.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | May. 03, 2023 (est.) |
| Last Earnings Release | Feb. 14, 2023 |
| Next Ex-Dividend Date | Apr. 20, 2023 |
| Last Ex-Dividend Date | Jan. 19, 2023 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 0.28 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.1568 |
| Yield to Sector | 23.09 |
| Yield to Industry | 0.6359 |
| Last Dividend Amt. | 0.07 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Jan. 19, 2023 |
| Yield (TTM) | 0.21% |
| Forward Yield | 0.21% |
| Payout Ratio | 6.21% |
| Cash Payout Ratio | 5.95% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 31, 2023.
Fundamentals
| Revenue (TTM) | 3.942B |
| Total Expenses (TTM) | 3.175B |
| Net Income (TTM) | 569.18M |
| Total Assets (Quarterly) | 14.13B |
| Total Liabilities (Quarterly) | 6.747B |
| Shareholders Equity (Quarterly) | 7.383B |
| Cash from Operations (TTM) | 679.81M |
| Cash from Investing (TTM) | -132.85M |
| Cash from Financing (TTM) | -661.80M |
Ratings
Profile
| PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes immunodiagnostics, reproductive health, and applied genomics, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software. |
| URL | https://www.perkinelmer.com |
| Investor Relations URL | https://ir.perkinelmer.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | May. 03, 2023 (est.) |
| Last Earnings Release | Feb. 14, 2023 |
| Next Ex-Dividend Date | Apr. 20, 2023 |
| Last Ex-Dividend Date | Jan. 19, 2023 |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| MJJ | 2.653M USD | 5.42% |
| THCX | 996852.0 USD | 4.18% |
| BBHLX | 93.31M USD | 4.09% |
| PINK | 858163.0 USD | 2.04% |
| PACLX | 822.83M USD | 1.81% |
| F00000Z1XG | 196.34M USD | 1.80% |
| RYH | 15.56M USD | 1.60% |
| ITCTX | 119.22M USD | 1.58% |
| HTEC | 1.569M USD | 1.57% |
| GURU | 679997.0 USD | 1.48% |
| MCPRX | 192.79M USD | 1.46% |
| CAFFX | 759.39M USD | 1.16% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PKI Tweets |